



1/7/2005

STR



G1 Me,Et,i-Bu,t-Bu,Ph,H,OH,X

ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB The title compds. (I) [wherein: X = CH, N; Y = C, CH or N, and when Y is CH or N, the optional covalent bond (represented by the dotted line between rings II and IV) is absent, and when Y is C, that optional covalent bond is present; G = (CHR4)n, CO; R = alkyl, OR4, aryl, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, cycloalkyl, cycloalkyloxy, etc.; one of a, b, c and d in ring I represents N or N+O-, and the remaining a, b, c and d positions represent C(R1) or C(R2); or each of a, b, c, and d are independently selected from C(R1) or C(R2) [R1, R2 = independently same or different, H, halo, CF3, OR4, COR4, OCF3, SR4, benzotriazol-1-yloxy, tetrazol-5-ylthio, alkynyl, alkenyl, etc.]; the dotted line between carbon atoms 5 and 6 represents an optional bond, such that when a double bond is present, A and B can be the same or different, each being independently selected from the group consisting of -R4, halo, -OR4, -CO2R4, -OCO2R4 or -O2CR4, and when no double bond is present between carbon atoms 5 and 6, A and B can be the same or different, each being independently selected from the group consisting of (H2), -(OR5)2, (H and halo), (dihalo), (H and R5), (R5)2, (H and -OC(O)R4), (H and -OR4), (:O), and (H, (:NOR4) or (-O(CH2)pO-) wherein p = 2-4); R3 = H, alkyl, alkoxy and alkoxyalkyl; R4 = H, alkyl, aryl, aralkyl; R5 = alkyl, aryl; R6 = H, alkyl; n = 1-4; q = 1-8] are prepared. These compds., e.g. (II), are inhibitors of type 3 17 β -hydroxysteroid dehydrogenase and used for

treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17 β -hydroxysteroid dehydrogenase such as (1) androgen dependent diseases including prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, (2) hair loss, and (3) proliferative diseases including lung cancer, pancreatic cancer, colon cancer, renal cancer, myeloid leukemia, thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, ovarian cancer, and prostate cancer. The compds. I exhibited a range of 17 β -hydroxysteroid dehydrogenase Type 3 binding activity from about 0.025 nM to about >100 nM. Several compds. of this invention had a binding activity in the range of about 0.025 nM to 10 nM.


IT 723301-24-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine derivs.
as 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for treatment
of androgen dependent diseases and proliferative diseases)

RN 723301-24-4 CAPLUS

CN 11H-Benzo[5,6]cyclohepta[1,2-b]pyridine-5-carboxylic acid,
11-[1'-(1-(aminocarbonyl)-4-piperidinyl)acetyl][4,4'-bipiperidin]-1-yl]-
3,8-dichloro-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






IT 723301-12-0P 723301-13-1P 723301-14-2P
 723301-16-4P 723301-17-5P 723301-18-6P
 723301-19-7P 723301-20-0P 723301-21-1P
 723301-22-2P 723301-23-3P 723301-35-7P
 723301-36-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine derivs.
 as 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for treatment
 of androgen dependent diseases and proliferative diseases)

RN 723301-12-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)






RN 723301-13-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 723301-14-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).




RN 723301-16-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 723301-17-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 723301-18-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-[2-[1'-(10-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-

oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 723301-19-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[2-[1'-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 723301-20-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidinyl]-1-yl]-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 723301-21-1 CAPLUS



CN 1-Piperidinecarboxamide, 4-[2-[1'-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).





RN 723301-22-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3,8-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)





RN 723301-23-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[1'-(3,9-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)





RN 723301-35-7 CAPLUS

CN 11H-Benzo[5,6]cyclohepta[1,2-b]pyridine-5-carboxylic acid,
11-[1'-[1-(aminocarbonyl)-4-piperidinyl]acetyl][4,4'-bipiperidin]-1-yl]-
3,8-dichloro- (9CI) (CA INDEX NAME)



RN 723301-36-8 CAPLUS
CN 4,4'-Bipiperidine, 1-[2-(1-acetyl-4-piperidinyl)acetyl]-1'-(3,8-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2004:570505 CAPLUS
 DOCUMENT NUMBER: 141:123570
 TITLE: Preparation of 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine derivatives as 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
 INVENTOR(S): Guzi, Timothy J.; Liu, Yi-Tsung; Doll, Ronald J.; Saksena, Anil; Girijavallabhan, Viyyoor M.; Pachter, Jonathan A.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 72 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004138226	A1	20040715	US 2003-735983	20031215
WO 2004060488	A1	20040722	WO 2003-US39863	20031215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				


HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV,
MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU,
SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN,
YU, ZA, ZM

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-434101P P 20021217
OTHER SOURCE(S): MAPPAT 141:123570

OTHER SOURCE(S): MARPAT 141:123570

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB Title compds. I [R1-3 = H, halo, haloalkyl, aryl, etc.; Q = S, O, amino; A = heterocycle, carbocycle] are prepared. For instance, 3-amino-4-chlorobenzamidoxime (preparation given) is reacted with 3-chlorothiophene-2-carbonyl chloride (pyridine, reflux, 50 min) to give II. II and other examples are potent caspase cascade activators and inducers of apoptosis in solid tumor cells, e.g., human breast cancer cell lines T-47D and ZR-75-1.


IT 193275-84-2, SCH66336

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



ACCESSION NUMBER: 2004:565086 CAPLUS
 DOCUMENT NUMBER: 141:123632
 TITLE: Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis
 INVENTOR(S): Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.;
 Zhang, Hong; Kemnitzer, William E.
 PATENT ASSIGNEE(S): Cytovia, Inc., USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058253	A1	20040715	WO 2003-US40308	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004127521	A1	20040701	US 2003-737865	20031218
PRIORITY APPLN. INFO.:			US 2002-433953P	P 20021218
OTHER SOURCE(S):	MARPAT	141:123632		

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI



AB Title compds. I [R1, R2 = (un)substituted alkyl, heterocycle; ALK1, ALK2 = (un)substituted secondary alkyl; L1 = linker; L2 = bond, linker; HET1 = (un)substituted saturated heterocycle containing N; m, n = 0, 1] and their pharmaceutically acceptable salts were prepared. For example, coupling reaction of {1-[(2E)-3-phenylprop-2-en-1-yl]piperidin-4-yl}acetic acid with 1,1-diphenylmethaneamine followed by treatment with fumaric acid, afforded compound I [R1 = benzhydryl; R2 = Ph; L2-(ALK2)n = CH2CH:CH2; HET1 = piperidine; L1-(ALK)m = 4-NHCOCH2] fumaric acid salt in 65% yield. In human melanin-concentrating hormone (MCH) inhibition assays, the IC50 value of compound I [R1 = benzhdryl; R2 = Ph; L2-(ALK2)n = CH2CH:CH2; HET1 = piperidine; L1-(ALK)m = 4-NHCOCH2] was 430 nM. Compds. I are claimed useful for treatment of obesity.

IT 696589-54-5P 696589-56-7P 696590-48-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperidines and related compds. as melanin-concentrating hormone

receptor antagonist for treatment of obesity)


RN 696589-54-5 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-1-[[1-[(2E)-3-phenyl-2-propenyl]-4-piperidinyl]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 696589-53-4
CMF C25 H30 N2 O


Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 696589-56-7 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-6-methyl-1-[[1-[(2E)-3-phenyl-2-propenyl]-4-piperidinyl]acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 696589-55-6
CMF C26 H32 N2 O


Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 696590-48-4 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-1-[(1-(2-naphthalenylmethyl)-4-piperidinyl)acetyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 696590-47-3

CMF C27 H30 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




ACCESSION NUMBER: 2004:453186 CAPLUS
DOCUMENT NUMBER: 141:23426
TITLE: Preparation of piperidines and related compounds as melanin-concentrating hormone receptor antagonist for treatment of obesity
INVENTOR(S): Kaku, Hidetaka; Kondoh, Yutaka; Hayashibe, Satoshi; Kamikubo, Takashi; Iwasaki, Fumiyo; Matsumoto, Shunichiro; Kimura, Yasuharu; Kurama, Takeshi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046110	A1	20040603	WO 2003-JP14534	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: JP 2002-332950 A 20021115
 OTHER SOURCE(S): MARPAT 141:23426
 REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI




AB N-Alkoxycarbonylpiperidines I [R = alkoxycarbonyl, R1 = O3SMe] were prep'd. by reacting I [R = aralkyl, R1 = OH] with a mesyl halide in the presence of a base to give I [R = aralkyl, R1 = O3SMe], and reacting this with a dicarbonate in the presence of hydrogen and a catalyst containing palladium to give I [R = alkoxycarbonyl, R1 = O3SMe]. Thus, 1-benzyl-4-piperidinone was treated with EtO2CCH2P(O)(OEt)2, reduced in two steps to 1-(1-benzyl-4-piperidinylacetyl)-4-piperidinol, mesylated, and treated with di-tert.-Bu carbonate in presence of H and Pd-C to give I [R = Boc, R1 = O3SMe].

IT 674301-86-1P 674301-87-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-alkoxycarbonylpiperidine derivs.)


RN 674301-86-1 CAPLUS

CN 4-Piperidinol, 1-[(1-(phenylmethyl)-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 674301-87-2 CAPLUS

CN 4-Piperidinol, 1-[(1-(phenylmethyl)-4-piperidinyl)acetyl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



ACCESSION NUMBER:

2004:247005 CAPLUS

DOCUMENT NUMBER:

140:270745

TITLE:

Methods of producing N-alkoxycarbonylpiperidine derivatives and intermediates therefor



INVENTOR(S):

Nakagawa, Kiyono

PATENT ASSIGNEE(S): Yuki Gosei Kogyo Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1400511	A1	20040324	EP 2003-20567	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004131486	A2	20040430	JP 2003-305662	20030829
US 2004063953	A1	20040401	US 2003-664074	20030917
PRIORITY APPLN. INFO.:	JP 2002-272173 A 20020918			
OTHER SOURCE(S):	MARPAT 140:270745			
REFERENCE COUNT:	2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI



AB Title compds. I [R1 = H, (un)substituted-alkyl, -alkanoyl, -aryl, or -arylalkyl; R2 = (un)substituted mono or bicyclic aromatic ring; R3 = arylalkylaminoalkyl, arylheterocyclalkyl, heterocyclheterocyclalkyl, etc.; R4 = H, (un)substituted-alkyl, -aryl, CN, halo, etc.; R5 = heterocyclcarbonylalkyl, halo, H, etc.] and their pharmaceutically acceptable salts are prepared and disclosed as gonadotropin releasing hormone antagonists. Thus, e.g., II, was prepared in a multistep synthesis from Et thiophen-2-ylacetate. In test assays, I possessed activity at concns. from 1nM to 5 μ M.

IT 666851-80-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thienopyrroles as antagonists of gonadotropin releasing hormone)

RN 666851-80-5 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[2-[5-(3,5-dimethylphenyl)-4-[2-[4-[2-oxo-2-(1-piperidinyl)ethyl]-1-piperidinyl]ethyl]-6H-thieno[2,3-b]pyrrol-2-yl]-2-methyl-1-oxopropyl] - (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2004:182888 CAPLUS
DOCUMENT NUMBER: 140:235695
TITLE: Preparation of 6H-thieno[2,3-b]pyrrole derivatives as antagonists of gonadotropin-releasing hormone (GnRh) for treating sex hormone related conditions
INVENTOR(S): Foote, Kevin Michael; Matusiak, Zbigniew; Dossetter, Alexander Graham; Arnould, Jean Claude; Lamorlette, Maryannick Andree; Delouvrie, Benedicte; Hamon, Annie
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018480	A1	20040304	WO 2003-GB3631	20030819
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2002-292074	A 20020821
OTHER SOURCE(S):			MARPAT 140:235695	
REFERENCE COUNT:	2		THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

AB The invention is directed to derivs. of gambogic acid and analogs thereof. Exemplary gambogic acid derivs. of the present invention include, among others, derivs. substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of

apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

IT 193275-84-2, SCH66336


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



ACCESSION NUMBER:

2004:20448 CAPLUS

DOCUMENT NUMBER:

140:87676

TITLE:

Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis

INVENTOR(S):

Tseng, Ben; Sirisoma, Nilantha Sudath; Cai, Sui Xiong; Zhang, Han-Zhong; Kasibhatla, Shailaja; Ollis, Kristin P.; Drewe, John A.

PATENT ASSIGNEE(S):

Cytovia, Inc., USA

SOURCE:

PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent


LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002428	A2	20040108	WO 2003-US20668	20030701
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004082066	A1	20040429	US 2003-609670	20030701
PRIORITY APPLN. INFO.:			US 2002-392358P	P 20020701
			US 2002-413649P	P 20020926



AB The title compds. I [wherein Ar = (un)substituted aryl, aralkyl, or heteroaryl; R1 = H, acyl, (un)substituted hydrocarbyl, or heterocyclyl; X = O or (un)substituted NH; Z = (un)substituted CH2; ring A = (un)substituted piperidine; ring B = (un)substituted aryl; with exclusions] or prodrugs or salts thereof are prepared I have excellent tachykinin receptor antagonistic activity, and are useful for the treatment of frequent urination and urinary incontinence (no data). For example, the compound II•xHCl was prepared in a multi-step synthesis. II showed antagonistic activity with IC50 of 0.025 nM against human substance P receptor. Formulations containing I as an active ingredient were also described.

IT 632349-24-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidine derivs. as tachykinin receptor antagonists for treatment of frequent urination and urinary incontinence)

RN 632349-24-7 CAPLUS

CN Piperidine, 1-[(1-acetyl-4-piperidinyl)acetyl]-4-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-phenyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



ACCESSION NUMBER: 2003:972057 CAPLUS
 DOCUMENT NUMBER: 140:27765
 TITLE: Preparation of piperidine derivatives as tachykinin receptor antagonists for treatment of frequent urination and urinary incontinence
 INVENTOR(S): Ikeura, Yoshinori; Hashimoto, Tadatoshi; Tarui, Naoki; Shirai, Junya; Yamashita, Masayuki
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 264 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101964	A1	20031211	WO 2003-JP6754	20030529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004285038	A2	20041014	JP 2003-154345	20030530
PRIORITY APPLN. INFO.:			JP 2002-159338	A 20020531
			JP 2003-17885	A 20030127
OTHER SOURCE(S): MARPAT	140:27765			
REFERENCE COUNT: 14	THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; one of a, b, d, e = N, N:O; remaining a, b, d, e = C (wherein each C atom has an R1 or R2 bound to said carbon); or each a, b, d, e = C (wherein each C atom has an R1 or R2); R1-R4 = H, halo, CF₃, alkoxy, etc.; R5-R7, R9 = H, CF₃, alkyl, aryl, etc.; R8 = H, alkoxy carbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, etc.; dotted line = single or double bond; X = N, CH; A, B = (un)substituted CH, CH₂], their stereoisomers, pharmaceutically acceptable salts, solvates, and prodrugs which are useful for inhibiting farnesyl protein transferase, were prepared E.g., a multi-step synthesis of II, was given. The compds. I have an FTP IC₅₀ in the range of 0.05 nM to 100 nM. Also disclosed are pharmaceutical compns. comprising title compds. I as well as methods of using them to treat proliferative diseases such as cancer.

IT 403486-25-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic antitumor compds. as farnesyl protein transferase inhibitors)


RN 403486-25-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[8-chloro-5-[(2-methyl-1H-imidazol-1-yl)methyl]-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



ACCESSION NUMBER:

2003:971730 CAPLUS

DOCUMENT NUMBER:

140:27844

TITLE:

Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors

INVENTOR(S):

Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-Yu; James, Ray A.; Bishop, W. Robert; Wang, James J. S.; Desai, Jagdish A.

PATENT ASSIGNEE(S):

USA

SOURCE: U.S. Pat. Appl. Publ., 519 pp., Cont.-in-part of U.S.

Pat. Appl. 2002 198,216.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003229099	A1	20031211	US 2002-85896	20020227
US 2002198216	A1	20021226	US 2001-940811	20010828
US 2004122018	A1	20040624	US 2002-325896	20021219
US 2004122018	A1	20040624	US 2002-325896	20021219
US 2004122018	A1	20040624	US 2002-325896	20021219
WO 2003072549	A1	20030904	WO 2003-US5479	20030225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1492772	A1	20050105	EP 2003-711214	20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2000-229183P	P 20000830
			US 2001-940811	A2 20010828
			US 2002-85896	A2 20020227
			US 2002-325896	A 20021219
			WO 2003-US5479	W 20030225

OTHER SOURCE(S): MARPAT 140:27844

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title pyridobenzocycloheptenes I [one of a-d = N, the others = (un)substituted CH; X = singly bonded N, singly or doubly bonded C; R, R2 = H, singly bonded substituent, R1, R3 = H; R1R3 = bond; R4 = (un)substituted CO2H, SO2H, CONH2, acyl; and the benzene and heterocyclic ring may have further substituents] which are used as an FPT inhibitor for the manufacture of a medicament for the treatment of cancer (e.g., non small cell lung cancer, squamous cell cancer of the head and neck, CML, AML, non-Hodgkin's lymphoma and multiple myeloma) in combination with therapeutically effective amts. of one or more antineoplastic agents, were prepared. A preferred compound is II.



IT 403486-25-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and use of pyridobenzocycloheptene derivs. as farnesyl protein transferase inhibitors for treating cancer)

RN 403486-25-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[8-chloro-5-[(2-methyl-1H-imidazol-1-yl)methyl]-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2003:454126 CAPLUS
 DOCUMENT NUMBER: 139:52885
 TITLE: Use of pyridobenzocycloheptene FPT inhibitors and at least two antineoplastic agents in the treatment of cancer
 INVENTOR(S): Cutler, David L.; Baum, Charles; Zaknoen, Sara L.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 406 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047586	A1	20030612	WO 2002-US38716	20021203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK,				

SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004006087 A1 20040108 US 2002-308813 20021203
 EP 1453513 A1 20040908 EP 2002-784716 20021203
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 PRIORITY APPLN. INFO.: US 2001-336961P P 20011203
 WO 2002-US38716 W 20021203
 OTHER SOURCE(S): MARPAT 139:52885
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI




AB Disclosed is a method of treating Malaria comprising administering to a patient in need of such treatment an effective amount of at least one farnesyl protein transferase (FPT) inhibitor alone or in combination with an addnl. antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are pharmaceutical compns. comprising at least one FPT inhibitor, in combination with at least one addnl. antimalaria agent and/or at least one addnl. agent for reversing antimalarial resistance, and a pharmaceutically acceptable carrier. Synthetic methods to prepare 15 of 26 claimed FPT inhibitors are provided. The claimed FPT inhibitors possessed ED50 values (μ M) of 0.05-5 in in vitro plasmodium falciparum growth inhibition assays. Specifically, I demonstrated an ED50 range of 0.05-0.2 in the assay.

IT 193275-84-2 193275-85-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (farnesyl protein transferase inhibitors disclosed for the treatment of
 malaria)

RN 193275-84-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193275-85-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



ACCESSION NUMBER: 2002:793399 CAPLUS
DOCUMENT NUMBER: 137:304744
TITLE: Treatment of malaria with farnesyl protein transferase inhibitors
INVENTOR(S): Windsor, William T.; Weber, Patricia C.; Strickland, Corey O.; Girijavallabhan, Viyyoor M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080895	A2	20021017	WO 2002-US10698	20020404

2002080895 A3 20031106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GO, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282092P P 20010406
US 2001-283107P P 20010411

OTHER SOURCE(S): MARPAT 137:304744

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

AB Disclosed is a method of treating malaria comprising administering an effective amount of a farnesyl protein transferase inhibitor to a patient in need of such treatment alone or in combination with an addnl. antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are novel farnesyl protein transferase inhibitors. Compds. of this invention exhibit a *P. falciparum* ED₅₀ range of between 0.05 μ M and 8.6 μ M.


IT 193275-84-2 193275-85-3

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of malaria with farnesyl protein transferase inhibitors and
preparation of tricyclic compds. for treatment)

RN 193275-84-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193275-85-3 CAPLUS

CN 1-Piperidinocarboxamide, 4-[2-[4-[(11S)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



ACCESSION NUMBER: 2002:555351 CAPLUS
 DOCUMENT NUMBER: 137:125178
 TITLE: Treatment of malaria with farnesyl protein transferase inhibitors and preparation of tricyclic compounds for said treatment
 INVENTOR(S): Windsor, William T.; Weber, Patricia C.; Wang, James J.-S.; Strickland, Corey; Njoroge, F. George; Guzi, Timothy J.; Girijavallabhan, Viyyoor M.; Ferreira, Johan A.; Desai, Jagdish A.; Cooper, Alan B.; Gelb, Michael
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056884	A2	20020725	WO 2002-US1637	20020118
WO 2002056884	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003092705	A1	20030515	US 2002-53335	20020118
US 6645966	B2	20031111		
US 2004087592	A1	20040506	US 2003-690232 US 2001-263277P	20031021 P 20010122
PRIORITY APPLN. INFO.:			US 2002-53335	A3 20020118

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; one of a, b, d, e = N, N:O; remaining a, b, d, e = C,

where each C has an R1 or R2; each a, b, d, e = C, where each C has an R1 or R2; R1, R2 independently = H, halo, CF3, alkoxy, alkylcarbonyl, alkylthio, aryloxy, arylcarbonyl, arylthio, heteroaryloxy, heterarylcarbonyl, heterarylthio; R3, R4 independently = H, halo, CF3, alkoxy, alkylcarbonyl, alkylthio, aryloxy, arylcarbonyl, arylthio, heteroaryloxy, heterarylcarbonyl, heterarylthio; R5, R6, R7, R9 independently = H, halo, CF3, alkoxy, alkylcarbonyl, alkylthio, aryloxy, arylcarbonyl, arylthio, heteroaryloxy, heterarylcarbonyl, heterarylthio; R5R6 = O, S; R8 = H, alkoxycarbonyl, aryloxycarbonyl, cycloalkoxycarbonyl, heteroaryloxycarbonyl, alkylsulfonyl, arylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, HONHCO, NCNHCO, CF3NHCO, R10R11NCO, R12R13R14CO; R10 = alkyl; R11 = H, OH, alkyl, aryl cycloalkyl heteroaryl; R12, R13, R14 independently = H, alkyl, aryl, cycloalkyl, heteroaryl; dotted line = single, double bond; X = N, CH; A = CH, CH2, CH], stereoisomers, pharmaceutically acceptable salts, solvates, and prodrugs are prepared and are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compns. comprising title compds. I and their preparation as well as methods of using them to treat proliferative diseases such as cancer. Title compds. I and other chemotherapeutic agents, selected from signal transduction inhibitors (bcr/abl kinase inhibitor, epidermal growth factor receptor inhibitor, her-2/neu receptor inhibitor), antineoplastic agents (uracil mustard, cyclo-phosphamide, etc.), microtubule affecting agents (Allocolchicine, Maytansine, etc.) are disclosed as pharmaceutical compns. Thus, the title compound II was prepared from 8-chloro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one, tert-Bu 1-piperazinecarboxylate, 2-methylimidazole, and p-cyanophenyl isocyanate via carbonation and hydrogenation.

IT

403486-25-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(preparation of tricyclic compds. being farnesyl protein transferase inhibitors)

RN

403486-25-9 CAPLUS

CN

1-Piperidinecarboxamide, 4-[2-[4-[8-chloro-5-[(2-methyl-1H-imidazol-1-yl)methyl]-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)





ACCESSION NUMBER: 2002:171884 CAPLUS
 DOCUMENT NUMBER: 136:232320
 TITLE: Preparation of tricyclic antitumor compounds being farnesyl protein transferase inhibitors
 INVENTOR(S): Njoroge, F. George; Vibulbhan, Bancha; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Santhanam, Bama; Pinto, Patrick A.; Zhu, Hugh Y.; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-yu; James, Ray A.; Bishop, Robert W.; Wang, James; Desai, Jagdish A.
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
 SOURCE: PCT Int. Appl., 405 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2002018368	A1	20020307	WO 2001-US26792	20010828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420673	AA	20020307	CA 2001-2420673	20010828
AU 2001088451	A5	20020313	AU 2001-88451	20010828
EP 1313725	A1	20030528	EP 2001-968188	20010828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013675	A	20030624	BR 2001-13675	20010828
JP 2004513885	T2	20040513	JP 2002-523486	20010828
NZ 524246	A	20041126	NZ 2001-524246	20010828
NO 2003000918	A	20030429	NO 2003-918	20030227
RTY APPLN. INFO.:			US 2000-229183P	P 20000830
			WO 2001-US26792	W 20010828

OTHER SOURCE(S): MARPAT 136:232320
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB Title compds. I [M = absent CH₂, CHR₅, CHR₁₃, CR₁₃R₁₃, and CR₅R₁₃; Q = CH₂, CHR₅, CHR₁₃, CR₁₃R₁₃, and CR₅R₁₃; K = CH₂, CHR₅ and CHR₆; J, L = CH₂, CHR₅, CHR₆, CR₆R₆ and CR₅R₆; with the provisons that at least one of M, J, K, L, or Q contains an R₅; and when M absent, J = CH₂, CHR₅, CHR₁₃ and CR₅R₁₃; Z = O, S, NR₁a, C(CN)2, CH(NO)2, CHCN; R₁a = H, (cyclo)alkyl, amido, alkoxy, CN, NO₂, etc.; E = C:O-alkyl, sulfonyl-alkyl, C:O-cycloalkyl; etc.; R₃ = alkylamino, alkyl-carbocyclic, etc.; R₅ = alkyl-carbocyclic; R₆ = alk(en/yn)yl, alkyl-cycloalkyl, CN, alkylamino, alkyl-hydroxy, etc.; R₁₃ = alk(en/yn)yl, cycloalkyl, alkyl-CF₃, alkylamino, alkyl-alkoxy; etc.] were prepared. Over 80 synthetic examples were disclosed. For instance, (1R,2R)-2-(benzyloxycarbonylamino)cyclohexanecarboxaldehyde (preparation given) was oxidized to the corresponding carboxylic

acid (NaOAc/HOAc, pH 3.5, CH₃CN, resorcinol, NaClO₂, 0°C, 16 h) and condensed with (S)-3-(4-fluorobenzyl)piperidine (preparation given; CH₂Cl₂, BOP, Et₃N, 0°C, 16 h) to give the amide. The intermediate Cbz group was removed (MeOH, 10% Pd/C, 50 psi H₂, overnight) and the amine acylated with 3-acetylphenylisocyanate (THF, 25°C) to give example compound II. I are modulators of chemokine receptor activity and are useful in the prevention of asthma and other allergic diseases.

IT 382638-09-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; synthesis of piperidine amides as modulators of chemokine receptor activity)

RN 382638-09-7 CAPLUS

CN Piperidine, 1-[[4-[[[(3-acetylphenyl)amino]carbonyl]amino]-1-methyl-4-piperidinyl]acetyl]-3-[(4-fluorophenyl)methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ACCESSION NUMBER: 2001:935573 CAPLUS
 DOCUMENT NUMBER: 136:53686
 TITLE: Synthesis of piperidine-amido-ureas as modulators of chemokine receptor activity
 INVENTOR(S): Duncia, John V.; Santella, Joseph B.; Wacker, Dean A.; Yao, Wenqing; Zheng, Changsheng
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 326 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098268	A2	20011227	WO 2001-US19705	20010620
WO 2001098268	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413418	AA	20011227	CA 2001-2413418	20010620
US 2002156102	A1	20021024	US 2001-885550	20010620

US 6638950	B2	20031028		
EP 1296949	A2	20030402	EP 2001-946580	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004516237	T2	20040603	JP 2002-504224	20010620
US 2004082790	A1	20040429	US 2003-635946	20030807
PRIORITY APPLN. INFO.:				
			US 2000-213066P	P 20000621
			US 2001-885550	A3 20010620
			WO 2001-US19705	W 20010620

OTHER SOURCE(S): MARPAT 136:53686

L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB The title compds. [I; R1 = C1-12 alkyl, (un)substituted CH2Ph, R2CO (wherein R2 = H, C1-12 alkyl optionally branched C1-12 alkoxy, optionally substituted aryl), allyl] or salts thereof are prepared by hydrolysis of tetrahydropyridineacetonitrile derivs. (II; R1 = same as above) which are in turn prepared by condensation of 4-piperidone derivs. [III; R1= H, C1-12 alkyl, (un)substituted CH2Ph, R2CO (wherein R2 = H, C1-12 alkyl optionally branched C1-12 alkoxy, optionally substituted aryl), allyl] with cyanoacetic acid. This process economically gives in an industrial scale the above compds. I which are useful as intermediates for an anticancer agent, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-5,6,11-trihydrobenzo[f]pyridino[2,3-b]cycloheptan-11-yl]-1-piperidyl]-2-oxoethyl]-1-piperidinecarboxamide (SCH-66336). Thus, 94.7 g 1-**benzyl**-4-piperidone and 51.1 g cyanoacetic acid were heated in 473.3 g toluene at 104-110° under reflux with azeotropically removing H2O for 2 h to give 97.1% 1-**benzyl**-4-(1,2,3,6-tetrahydropyridine)acetonitrile (IV) which converted into the HCl salt in 57.0% yield by treatment with HCl in AcOEt. IV.HCl (5.0 g) was heated in 8.4 g 35% aqueous HCl at 80° for 5 h to give 86.6% 1-**benzyl**-4-1,2,3,6-tetrahydropyridineacetic acid.


IT 193275-84-2P, SCH-66336

RL: PNU (Preparation, unclassified); PREP (Preparation)
(preparation of tetrahydropyridineacetic acids or their salts as intermediate for anticancer SCH-66336 by condensation of piperidone derivs. with cyanoacetic acid and hydrolysis of tetrahydropyridineacetonitrile derivs.)

RN 193275-84-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



ACCESSION NUMBER: 2001:932501 CAPLUS
 DOCUMENT NUMBER: 136:53684
 TITLE: Tetrahydropyridineacetic acids or their salts and their intermediates and method for preparing them
 INVENTOR(S): Hayashi, Taketo; Nishiwaki, Kenji
 PATENT ASSIGNEE(S): Sumika Fine Chemicals Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001354653	A2	20011225	JP 2000-171923	20000608
PRIORITY APPLN. INFO.:			JP 2000-171923	20000608
OTHER SOURCE(S):	CASREACT 136:53684; MARPAT 136:53684			


L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. (I) [wherein a, b, c, and d = N or NR9; R1, R3, and R4 = halo; R2 = H; R5, R6, R7, and R8 = independently H, CF3, COR10, (un)substituted alkyl or aryl, :O, or :S; R9 = :O, Me, or (CH2)nCO2H; R10 = H, (ar)alkyl, or aryl; R11 = alkyl or aryl; R12 = H, (ar)alkyl, heteroarylalkyl; R13 and R14 = independently H, carboxy, sulfamido, acyl, (ar)alkyl, cycloalkyl, etc.; X = CH or C; A and B = independently R10, halo, OR11, OCO2R11, OC(O)R10, H2, (OR11)2, H and halo, dihalo, H and alkyl, (alkyl)2, H and OC(O)R10, H and OR10, H and aryl, :O, :NOR10, or O(CH2)pO; W = C(O)CHR12(CH2)rNR13R14; n = 1-3; p = 2-4; r = 0-2] were prepared as antitumor agents. The compds. of the invention inhibit farnesyl protein transferase (FPT) and farnesylation of the oncogene protein Ras, thereby blocking abnormal cell growth. Examples include syntheses and bioassay data for over 100 title compds. For instance, the piperidine derivative II (preparation given) underwent a sequence of: (1) acylation with N-BOC-glycine (85%); (2) N-deprotection with TFA (68%); and (3) sulfamidation with MeSO2Cl in the presence of TEA (89%), to give the title compound III. The latter inhibited farnesyl protein transferase in vitro with IC50 of 5 nM and inhibited Ras processing in a COS cell-based assay with IC50 of 30 nM.

IT 210646-40-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of benzo[5,6]cyclohepta[1,2-b]pyridines as farnesyl protein transferase inhibitors for the treatment of cancer)
 RN 210646-40-5 CAPLUS
 CN Piperidine, 1-(chloroacetyl)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 210646-05-2P 210646-06-3P 210646-07-4P
 210646-09-6P 210646-11-0P 210646-12-1P
 210646-17-6P 210646-31-4P 210646-53-0P
 210646-54-1P 210646-59-6P 210646-76-7P
 210646-77-8P 210646-80-3P 210646-94-9P
 259528-12-6P 259528-15-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compound; preparation of benzo[5,6]cyclohepta[1,2-b]pyridines as farnesyl protein transferase inhibitors for the treatment of cancer)

RN 210646-05-2 CAPLUS
 CN Carbamic acid, [2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 210646-06-3 CAPLUS

CN Piperidine, 1-(aminoacetyl)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 210646-07-4 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-09-6 CAPLUS

CN Carbamic acid, [(1R)-2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-11-0 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-12-1 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-17-6 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-(4-morpholinylacetyl)-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-31-4 CAPLUS

CN 1-Piperidinepentanoic acid, β -(acetyloxy)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- δ -oxo-, ethyl ester, (β R)- (9CI)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-53-0 CAPLUS

CN Carbamic acid, [3-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-54-1 CAPLUS

CN Carbamic acid, [4-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-59-6 CAPLUS

CN 1-Piperidinehexanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- ϵ -oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-76-7 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-beta-oxo-, lithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Li

RN 210646-77-8 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-gamma-oxo-, lithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Li

RN 210646-80-3 CAPLUS

CN 1-Piperidinehexanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-ε-oxo-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 210646-94-9 CAPLUS

CN 1-Piperidinepentanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-β-hydroxy-δ-oxo-, (βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259528-12-6 CAPLUS

CN 1-Piperidineheptanoic acid, 4-[2-[4-[{(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl}-1-piperidiny1]-2-oxoethyl]- ζ -oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259528-15-9 CAPLUS

CN 1-Piperidineheptanoic acid, 4-[2-[4-[{(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl}-1-piperidinyl]-2-oxoethyl]- ζ -oxo-, lithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

IT 210646-08-5P 210646-10-9P 210646-14-3P
 210646-15-4P 210646-18-7P 210646-19-8P
 210646-20-1P 210646-21-2P 210646-22-3P
 210646-23-4P 210646-24-5P 210646-25-6P
 210646-26-7P 210646-27-8P 210646-28-9P
 210646-29-0P 210646-30-3P 210646-33-6P
 210646-37-0P 210646-41-6P 210646-42-7P
 210646-43-8P 210646-44-9P 210646-45-0P
 210646-46-1P 210646-47-2P 210646-48-3P
 210646-49-4P 210646-51-8P 210646-52-9P
 210646-56-3P 210646-57-4P 210646-58-5P
 210646-60-9P 210646-62-1P 210646-63-2P
 210646-64-3P 210646-65-4P 210646-66-5P
 210646-67-6P 210646-68-7P 210646-69-8P
 210646-70-1P 210646-71-2P 210646-72-3P
 210646-73-4P 210646-74-5P 210646-75-6P
 210646-78-9P 210646-81-4P 210646-82-5P
 210646-83-6P 210646-84-7P 210646-85-8P
 210646-86-9P 210646-87-0P 210646-88-1P
 210646-89-2P 210646-90-5P 210646-91-6P
 210646-92-7P 210646-93-8P 210646-96-1P
 210646-98-3P 210646-99-4P 210647-00-0P
 210697-36-2P 210697-37-3P 210697-38-4P
 210697-39-5P 259528-10-4P 259528-11-5P
 259528-13-7P 259528-14-8P 259528-17-1P
 259528-18-2P 259539-20-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of benzo[5,6]cyclohepta[1,2-b]pyridines as farnesyl protein transferase inhibitors for the treatment of cancer)

RN 210646-08-5 CAPLUS

CN Piperidine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-10-9 CAPLUS

CN Piperidine, 1-[(2R)-2-amino-1-oxopropyl]-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzocyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-14-3 CAPLUS

CN Piperidine, 1-[(2S)-2-amino-1-oxo-3-phenylpropyl]-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzocyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-15-4 CAPLUS

CN Piperidine, 1-[(2S)-2-amino-3-(1H-imidazol-4-yl)-1-oxopropyl]-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-18-7 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-(1H-imidazol-1-ylacetyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-19-8 CAPLUS

CN 1-Piperidineacetamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 210646-20-1 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-[(methylsulfonyl)amino]acetyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-21-2 CAPLUS

CN Benzamide, N-[2-[4-[2-[4-[11R]-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-22-3 CAPLUS

CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[[1-[4-(dimethylamino)-1-oxobutyl]-4-piperidinyl]acetyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 210646-23-4 CAPLUS

CN Piperidine, 4-(3,10-dibromo-8-chloro-6,10-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[[1-[3-(dimethylamino)-1-oxopropyl]-4-piperidinyl]acetyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 210646-24-5 CAPLUS

CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[[1-[(dimethylamino)acetyl]-4-piperidinyl]acetyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 210646-25-6 CAPLUS

CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-[1-oxo-3-(1-piperidinyl)propyl]-4-piperidinyl)acetyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 210646-26-7 CAPLUS


CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-[(1,1-dioxido-4-thiomorpholinyl)acetyl]-4-piperidinyl)acetyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 210646-27-8 CAPLUS
CN 1-Piperidinpentanoic acid, 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]- δ -oxo-, methyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 210646-28-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]- γ -oxo-, methyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 210646-29-0 CAPLUS
CN 1-Piperidinepropanoic acid, 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]- β -oxo-, ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 210646-30-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(1-methylethylidene)amino]oxy]acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-33-6 CAPLUS


CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(3-[(1-methylethylidene)amino]oxy)-1-oxopropyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-37-0 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-(1H-imidazol-4-ylacetyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-41-6 CAPLUS
CN Piperidine, 1-(cyanoacetyl)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210646-42-7 CAPLUS
CN 1-Piperidineacetamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-N-methoxy- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-43-8 CAPLUS

CN 1-Piperidinepropanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-β-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-44-9 CAPLUS


CN 1-Piperidinepropanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-N-(1-methoxy-2-methylpropyl)-β-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-45-0 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-(1,2-dioxopropyl)-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-46-1 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-(1-piperidinylacetyl)-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210646-47-2 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-(3,3-diethoxy-1-oxopropyl)-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-48-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,10-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(2,4-dioxo-4-imidazolidinyl)acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-49-4 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,10-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(2,5-dioxo-3-thiazolidinyl)acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-51-8 CAPLUS

CN Piperidine, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-(2-thienylacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-52-9 CAPLUS

CN Piperidine, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-[(tetrahydro-2H-pyran-4-yl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-56-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-(1,4-dioxan-2-ylacetyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-57-4 CAPLUS

CN Piperidine, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-[(tetrahydro-2H-pyran-2-yl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-58-5 CAPLUS

CN Piperidine, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-[(tetrahydro-2-furanyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-60-9 CAPLUS

CN 1-Piperidinepentanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-δ-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-62-1 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-[(4-methyl-1H-imidazol-1-yl)acetyl]-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-63-2 CAPLUS

CN Piperidine, 1-(1H-benzimidazol-1-ylacetyl)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-64-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-(1H-imidazo[4,5-b]pyridin-1-ylacetyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-65-4 CAPLUS


CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(4-phenyl-1H-imidazol-1-yl)acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-66-5 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(4-nitro-1H-imidazol-1-yl)acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-67-6 CAPLUS
CN Piperidine, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-(1H-pyrrol-1-ylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210646-68-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-69-8 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-70-1 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 1-[2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-71-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 1-[2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-72-3 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-73-4 CAPLUS

CN 1H-Imidazole-4-acetic acid, 1-[2-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-74-5 CAPLUS

CN Piperidine, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-(1H-1,2,4-triazol-1-ylacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 210646-75-6 CAPLUS

CN 1-Piperidineacetic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-78-9 CAPLUS

CN 1-Piperidinepentanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-8-oxo-, lithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Li

RN 210646-81-4 CAPLUS

CN 1-Piperidinehexanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-ε-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-82-5 CAPLUS

CN 1-Piperidinebutanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-γ-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-83-6 CAPLUS

CN 1-Piperidineheptanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-zeta-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-84-7 CAPLUS

CN 1-Piperidinepentanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-delta-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-85-8 CAPLUS

CN 1-Piperidineacetic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- α -oxo-, hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-86-9 CAPLUS

CN 1-Piperidineacetamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-N-hydroxy- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-87-0 CAPLUS

CN Glycine, N-[[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]oxoacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-88-1 CAPLUS

CN 1-Piperidineacetamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- α -oxo-N-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-89-2 CAPLUS


CN 1-Piperidineacetamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-N-methyl- α -oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-90-5 CAPLUS
CN Piperidine, 1-(3-amino-1-oxopropyl)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210646-91-6 CAPLUS
CN Piperidine, 1-(4-amino-1-oxobutyl)-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210646-92-7 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[[[(dimethylamino)sulfonyl]amino]acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-93-8 CAPLUS

CN Piperidine, 1-[(aminosulfonyl)amino]acetyl]-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-96-1 CAPLUS

CN 1-Piperidinepentanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-β-hydroxy-δ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-98-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[1,3-dioxo-3-(1-piperidinyl)propyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210646-99-4 CAPLUS

CN Morpholine, 4-[3-[4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinyl]-1,3-dioxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210647-00-0 CAPLUS

CN 1-Piperidinepropanamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-N,N-dimethyl-β-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210697-36-2 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(1,1-dioxido-4-thiomorpholinyl)acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210697-37-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(1-oxo-3-(1-piperidinyl)propyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210697-38-4 CAPLUS

CN 1-Piperidinopropanoic acid, 4-[2-[4-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210697-39-5 CAPLUS

1-Piperidinebutanoic acid, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-γ-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259528-10-4 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[[[[(E)-[(1-oxido-4-pyridinyl)methylene]amino]oxy]acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 259528-11-5 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-(hydroxyacetyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259528-13-7 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(E)-[(2-hydroxyphenyl)methylene]amino]oxy]acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 259528-14-8 CAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[[1-[(2-methyl-1H-imidazol-1-yl)acetyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259528-17-1 CAPLUS
CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[[1-[4-(dimethylamino)-1-oxobutyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 259528-18-2 CAPLUS
CN Piperidine, 4-(3,10-dibromo-8-chloro-6,10-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[[1-[3-(dimethylamino)-1-oxopropyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 259539-20-3 CAPLUS

CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-[(dimethylamino)acetyl]-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER:

2000:142525 CAPLUS

DOCUMENT NUMBER:

132:180486

TITLE:

Preparation of benzo[5,6]cyclohepta[1,2-b]pyridines for the inhibition of farnesyl protein transferase

INVENTOR(S):

Njoroge, F. George; Taveras, Arthur G.; Doll, Ronald J.; Lalwani, Tarik; Alvarez, Carmen; Remiszewski, Stacy W.

PATENT ASSIGNEE(S):

Schering Corporation, USA

SOURCE:

U.S., 73 pp.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6030982	A	20000229	US 1997-927731	19970911
US 6040305	A	20000321	US 1997-927470	19970911
US 6228856	B1	20010508	US 1999-417885	19991014
US 2002019400	A1	20020214	US 2001-797081	20010301
US 6387905	B2	20020514		
PRIORITY APPLN. INFO.:			US 1996-25249P	P 19960913
			US 1997-50009P	P 19970617
			US 1996-26114P	P 19960913
			US 1997-927731	A3 19970911
			US 1999-417885	A3 19991014
OTHER SOURCE(S):	MARPAT 132:180486			
REFERENCE COUNT:	33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds., e.g., I [W = cyano, etc.; R1 = H, halo, etc.; R3, R4 = H, halo, CF₃, etc.; or R3R4 = saturated or unsatd. C5 - C7 fused ring to the benzene ring; X represents N, CH, or C, which C may contain an optional double bond (represented by the dotted line); dotted line represents an optional double bond; when such a double bond is present between the two C atoms bearing A and B, A and B independently represent R10, halo, etc.; when no such double is present, A and B each independently represent H₂, (OR11)₂, H and halo, dihalo, etc.; R10 = H, alkyl, etc.; R11 = alkyl, aryl] are prepared. The title compound II in vitro showed IC₅₀ of 0.1 μM against farnesyl protein transferase.

IT 204712-34-5P 204712-53-8P 204712-74-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. useful for inhibition of farnesyl protein transferase)

RN 204712-34-5 CAPLUS

CN Piperidine, 1-acetyl-4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204712-53-8 CAPLUS


CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-formyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204712-74-3 CAPLUS

CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-[1-(methylamino)-2-nitroethenyl]-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER:

1999:53389 CAPLUS

DOCUMENT NUMBER:

130:139358

TITLE:

Preparation and formulation of tricyclic compounds useful for inhibition of farnesyl protein transferase
Taveras, Arthur G.; Mallams, Alan K.; Afonso, Adriano; Remiszewski, Stacy W.; Njoroge, F. George; Doll, Ronald; Lalwani, Tarik; Alvarez, Carmen

INVENTOR(S):

Schering Corporation, USA
U.S., 71 pp.

PATENT ASSIGNEE(S):

SOURCE:

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:



English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5861395	A	19990119	US 1997-927469	19970911
PRIORITY APPLN. INFO.:			US 1997-927469	19970911
OTHER SOURCE(S):	MARPAT 130:139358			
REFERENCE COUNT:	28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
GI


AB Title compds. [I; A, B = H₂, O, halo, alkyl, alkoxy, etc.; ≤1 of a-d = N or NR₉ and the others = CR₁ or CR₂; R = (hetero)aryl(methyl), etc.; R₁, R₂ = H, halo, OH, alkoxy(carbonyl), etc.; R₃, R₄ = groups cited for R₁; R₅-R₈ = H, alkyl, aryl, etc.; R₉ = O, Me, (CH₂)₁₋₃CO₂H; Z = O, S; dashed lines = optional bonds], capable of inhibiting Ras function and therefore inhibiting the abnormal growth of cells, were prepared. Thus, benzocycloheptapyridine derivative II (R₁₀ = H) (preparation given) was amidated by pyridine-4-acetic acid to give II (R₁₀ = 4-pyridylacetyl). II (R₁₀ = 3-pyridylacetyl) gave 61.2% inhibition of mouse Lewis lung carcinoma in nu/nu mice at 100mg/kg BID for 4 wk.

IT 183198-40-5P 183481-24-5P 183481-31-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic amide and urea compds. for inhibition of G-protein function and treatment of proliferative diseases)


RN 183198-40-5 CAPLUS

CN Piperidine, 4-(3-bromo-8-chloro-6,11-dihydro-11-methyl-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 183481-24-5 CAPLUS

CN Piperidine, 4-(3-bromo-8-chloro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 183481-31-4 CAPLUS

CN Piperidine, 4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1998:146564 CAPLUS
 DOCUMENT NUMBER: 128:180340
 TITLE: Preparation of tricyclic amide and urea compounds for inhibition of G-protein function and treatment of proliferative diseases
 INVENTOR(S): Bishop, W. Robert; Doll, Ronald J.; Mallams, Alan K.; Njoroge, F. George; Petrin, Joanne M.; Piwinski, John J.; Wolin, Ronald L.; Taveras, Arthur G.; Remiszewski, Stacy W.
 PATENT ASSIGNEE(S): Schering Corp., USA
 SOURCE: U.S., 215 pp., Cont.-in-part of U.S. Ser. No. 312,028, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5719148	A	19980217	US 1995-410187	19950324
EP 1123931	A1	20010816	EP 2001-109408	19941012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 5696121	A	19971209	US 1995-450288	19950525
US 5714609	A	19980203	US 1995-450064	19950525
US 5807853	A	19980915	US 1995-450433	19950525
CA 2216160	AA	19961003	CA 1996-2216160	19960321
CA 2216160	C	20011030		
WO 9630363	A1	19961003	WO 1996-US3314	19960321
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9653077	A1	19961016	AU 1996-53077	19960321
AU 714255	B2	19991223		
EP 815100	A1	19980107	EP 1996-909651	19960321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

LV, FI				
JP 10505105	T2	19980519	JP 1996-529434	19960321
JP 3368905	B2	20030120		
AU 9892399	A1	19990204	AU 1998-92399	19981116
AU 735262	B2	20010705		
US 6365588	B1	20020402	US 1999-350870	19990709
US 6242458	B1	20010605	US 1999-400714	19990921
US 2002068742	A1	20020606	US 2001-829264	20010409
US 2003055065	A1	20030320	US 2001-26751	20011220
PRIORITY APPLN. INFO.:				
		US 1993-137862	B2	19931015
		US 1994-312028	B2	19940926
		AU 1994-79703	A3	19941012
		EP 1994-930650	A3	19941012
		US 1995-410187	A1	19950324
		US 1995-450288	A3	19950525
		WO 1996-US3314	W	19960321
		US 1997-971038	B1	19971114
		US 1998-22137	B1	19980211
		US 1999-350870	A3	19990709
		US 1999-400714	A3	19990921

OTHER SOURCE(S): MARPAT 128:180340
 REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
 GI For diagram(s), see printed CA Issue.
 AB Piperidineacetic acid derivs. I (R = H, F, R1 = alkoxy, substituted amino, X = CHMe, CHEt, cyclohexylmethyl, 1,1-cycloalkanediyl etc.) and II (R3 = H, Cl) were prepared and were analgesic in the tail-flick test in mice at 1-30 mg/kg s.c. Thus treatment of EtCO₂Et with 1-**benzyl**-4-piperidinone gave Et 2-(1-**benzyl**-4-hydroxy-4-piperidyl)propionate, which was debenzylated and treated with Bz(CH₂)₃Cl to give I (R = H, R1 = OEt, X = CHMe).
 IT 55313-78-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55313-78-5 CAPLUS
 CN Piperidine, 1-[2-[1-[2-(2-chlorophenyl)ethyl]-4-hydroxy-4-piperidinyl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1975:156102 CAPLUS
DOCUMENT NUMBER: 82:156102
TITLE: 4-Hydroxy-4-piperidineacetic acid derivative analgesics
INVENTOR(S): Rissi, Erwin; Ebnoether, Anton
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 69 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2429373	A1	19750116	DE 1974-2429373	19740619
CH 587812	A	19770513	CH 1973-9177	19730622
CH 586198	A	19770331	CH 1973-9414	19730628
CH 587822	A	19770513	CH 1973-9509	19730629
CH 586199	A	19770331	CH 1973-9598	19730702
BE 816724	A1	19741223	BE 1974-145766	19740621
ZA 7404025	A	19760128	ZA 1974-4025	19740621
			CH 1973-9177	A 19730622
			CH 1973-9414	A 19730628
			CH 1973-9509	A 19730629
			CH 1973-9598	A 19730702

=>